Bausch + Lomb

Company snapshot

Bausch + Lomb is a leading global eye health business that is solely focused on helping people see better to live better. Our core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. We develop, manufacture and market one of the most comprehensive product p

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Bausch + Lomb. Not investment advice.

• What is Bausch + Lomb?

  Bausch + Lomb is a pharma organization headquartered in GB. Primary therapeutic focus areas include Colitis, Ulcerative. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO source

• Is Bausch + Lomb publicly traded?

  Bausch + Lomb appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Bausch + Lomb develop or market?

  We link 2 drug profile(s) where Bausch + Lomb is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/bausch-lomb-ireland-limited#company-drugs.

• What are the latest developments for Bausch + Lomb?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Bausch + Lomb focus on?

  Bausch + Lomb focuses on Colitis, Ulcerative based on our analysis of their pipeline programs and drug development activities.